Published by Global Banking & Finance Review®
Posted on March 17, 2025
2 min readLast updated: January 24, 2026
Add as preferred source on GoogleNovartis CEO Vas Narasimhan is monitoring US reciprocal tariff policies closely, as potential 25% import duties on pharmaceuticals could impact global trade.
TOKYO (Reuters) -Swiss pharmaceutical giant Novartis will watch "very carefully" how the reciprocal tariff policy proposed by the United States unfolds in early April, Chief Executive Vas Narasimhan said on Monday.
U.S. President Donald Trump last month flagged potential import duties of about 25% on pharmaceuticals as part of measures affecting a range of industries, including semiconductors and automobiles, as he seeks to reshape global trade.
"The real key is to see what are the policies that are actually implemented versus what's being said in the rhetoric," Narasimhan told reporters at a briefing in Tokyo. "And then we're just going to have to respond appropriately."
Trump said on Monday he had no intention of creating exemptions from steel and aluminium tariffs and said he will impose reciprocal and sectoral tariffs on April 2.
The U.S. president has previously announced tariffs on trade partners only to subsequently suspend them or allow exceptions.
Narasimhan was in Japan to announce plans to set up a research hub employing about 50 people to expand Novartis' clinical trials in the East Asian country.
That would follow a $100 million investment in its Sasayama facility in western Japan, announced in 2024, to grow production of radiopharmaceuticals - a form of targeted nuclear medicine used to treat multiple types of cancer.
Last year, Novartis agreed to buy U.S.-based Mariana Oncology for $1 billion upfront to expand its portfolio of the drugs, which currently include prostate cancer treatment Pluvicto and Lutathera used for a rare group of gastrointestinal tumours.
(Reporting by Rocky Swift; Editing by Kim Coghill and Christopher Cushing)
The article discusses Novartis CEO Vas Narasimhan's response to US reciprocal tariff policies affecting pharmaceuticals.
Proposed 25% import duties on pharmaceuticals could impact Novartis' operations and global trade strategies.
Novartis plans to set up a research hub in Japan, expanding clinical trials and investing in radiopharmaceutical production.
Explore more articles in the Headlines category
